- Home
- LVS vs RPRX Comparison
LVS vs RPRX Comparison
Compare LVS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVS | RPRX |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | 100 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 25.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LVS | RPRX |
|---|---|---|
| Price | $38.74 | $58.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $69.21 | $51.40 |
| AVG Volume (30 Days) | ★ 4.8M | 2.9M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | 1.90% |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 1.38 | 0.71 |
| Revenue | ★ $13,017,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $7.24 | $38.63 |
| Revenue Next Year | $4.49 | $4.73 |
| P/E Ratio | ★ $28.24 | $82.06 |
| Revenue Growth | ★ 15.22 | 5.06 |
| 52 Week Low | $38.06 | $34.96 |
| 52 Week High | $70.45 | $64.38 |
Technical Indicators
Market Signals| Indicator | LVS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.38 | 46.02 |
| Support Level | N/A | $57.75 |
| Resistance Level | $55.13 | $58.84 |
| Average True Range (ATR) | 0.97 | 1.24 |
| MACD | -0.24 | -0.20 |
| Stochastic Oscillator | 10.84 | 33.75 |
Price Performance
Historical ComparisonAbout LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.